Floatz logo

OPA-INTERACTING PROTEIN 4

Bone Sarcomas

Mannkind Corporationprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Bone Sarcomas cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Essen Biotech
Phase 2BB
Fludarabine
Essen Biotech
Phase 2B
Lifileucel
M.D. Anderson Cancer Center
Phase 2CCC
TEONANACATL
University Health Network, Toronto
Phase 2CCC
Ipilimumab
M.D. Anderson Cancer Center
Phase 2CCC

View all 12 →

Same molecule, other indications

OPA-INTERACTING PROTEIN 4 is also rated in:

ovarian disorderDormant
CC
Indicative ·
47 / 100
View asset →
kidney disorderDormant
CC
Indicative ·
47 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →